Cantargia AB (CHIX:CANTAS) Beginning Cash Position: kr281.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:CANTAS Cantargia AB CHIX:CANTAS
33 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB Beginning Cash Position?

Cantargia AB CHIX:CANTAS 33 Beginning Cash Position is kr281.8 Mil as of Mar. 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Cantargia AB's Beginning Cash Position for the quarter that ended in Mar. 2026 was kr281.8 Mil.

Cantargia AB's quarterly Beginning Cash Position increased from Sep. 2025 (kr81.9 Mil) to Dec. 2025 (kr339.1 Mil) but then declined from Dec. 2025 (kr339.1 Mil) to Mar. 2026 (kr281.8 Mil).

Cantargia AB's annual Beginning Cash Position declined from Dec. 2023 (kr189.6 Mil) to Dec. 2024 (kr139.7 Mil) and declined from Dec. 2024 (kr139.7 Mil) to Dec. 2025 (kr33.0 Mil).

Cantargia AB Beginning Cash Position Related Terms

Cantargia AB Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Cantargia AB's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB Beginning Cash Position Chart

Cantargia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 693.36 247.32 189.57 139.75 33.04

Cantargia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.04 103.93 81.88 339.12 281.82
CHIX:CANTAS
33GF Score
Cantargia AB CHIX:CANTAS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr281.8 Mil mean?
Cantargia AB (CHIX:CANTAS) has a Beginning Cash Position of kr281.8 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Cantargia AB and its competitors.
Is Cantargia AB's Beginning Cash Position too high?
Cantargia AB's current Beginning Cash Position is kr281.8 Mil. Overall, Cantargia AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's Beginning Cash Position compare to VRTX and REGN?
Cantargia AB's Beginning Cash Position of kr281.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Cantargia AB and its competitors. Cantargia AB's current Beginning Cash Position is kr281.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current Beginning Cash Position of kr281.8 Mil. The current Beginning Cash Position is kr281.8 Mil. Cantargia AB's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current Beginning Cash Position is kr281.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
33GF Score

Get the complete analysis for CHIX:CANTAS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price